{"id":7784,"date":"2023-04-04T17:11:44","date_gmt":"2023-04-04T16:11:44","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=7784"},"modified":"2023-04-04T17:14:51","modified_gmt":"2023-04-04T16:14:51","slug":"ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/","title":{"rendered":"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h3 class=\"Default\">04\/04\/2023 \u2013\u00a0AB Science communique aujourd&rsquo;hui une mise \u00e0 jour du calendrier des proc\u00e9dures d\u2019\u00e9valuation par l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA) et par Sant\u00e9 Canada de ses demandes d&rsquo;autorisation conditionnelle du masitinib dans le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique (SLA)<\/h3>\n<h3 class=\"Default\"><\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMy8wNC9SZWd1bGF0b3J5LXN0YXR1cy1BTFMtVkZSLVZGLnBkZiZzZXR0aW5ncz0xMTEwMTExMTExMTExMTExMTAwJmxhbmc9ZW4tVVM=#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-c7ee4d1996d1e8a11e0cbb08e3d780e4.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-c7ee4d1996d1e8a11e0cbb08e3d780e4 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2023\/04\/Regulatory-status-ALS-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1680624692264\" target=\"_blank\" id=\"default-btn-c7ee4d1996d1e8a11e0cbb08e3d780e4\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] 04\/04\/2023 \u2013\u00a0AB Science communique aujourd&rsquo;hui une mise \u00e0 jour du calendrier des proc\u00e9dures d\u2019\u00e9valuation par l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA) et par Sant\u00e9 Canada de ses demandes d&rsquo;autorisation conditionnelle du masitinib dans le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique (SLA) [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132],"tags":[],"class_list":["post-7784","post","type-post","status-publish","format-standard","hentry","category-2023-fr","category-132","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada<\/title>\n<meta name=\"description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada\" \/>\n<meta property=\"og:description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T16:11:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T16:14:51+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada\",\"datePublished\":\"2023-04-04T16:11:44+00:00\",\"dateModified\":\"2023-04-04T16:14:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\\\/\"},\"wordCount\":184,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"articleSection\":[\"2023\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\\\/\",\"name\":\"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2023-04-04T16:11:44+00:00\",\"dateModified\":\"2023-04-04T16:14:51+00:00\",\"description\":\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/","og_locale":"fr_FR","og_type":"article","og_title":"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada","og_description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","og_url":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/","og_site_name":"AB Science","article_published_time":"2023-04-04T16:11:44+00:00","article_modified_time":"2023-04-04T16:14:51+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada","datePublished":"2023-04-04T16:11:44+00:00","dateModified":"2023-04-04T16:14:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/"},"wordCount":184,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"articleSection":["2023"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/","url":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/","name":"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2023-04-04T16:11:44+00:00","dateModified":"2023-04-04T16:14:51+00:00","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"AB Science annonce avoir r\u00e9pondu aux questions au D120 de la proc\u00e9dure EMA de demande d\u2019autorisation conditionnelle du masitinib dans la scl\u00e9rose lat\u00e9rale amyotrophique et pr\u00e9cise le nouveau calendrier de r\u00e9ponse \u00e0 Sant\u00e9 Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/7784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=7784"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/7784\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=7784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=7784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=7784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}